|
Target day
|
0
|
21 +/−3
|
42 +/−3
|
90 +/−7
|
360 +/−14
| |
|
Eligibility screening, history
|
x
| | | | | |
|
Randomization
|
x
| | | | | |
|
VSS-SF
|
x
|
x
|
x
|
x
|
x
|
Primary endpoint, at 6 weeks
|
|
EQ-5D
|
x
|
x
|
x
|
x
|
x
| |
|
DHI
|
x
| |
x
|
x
| | |
|
T25-FW
|
x
| |
x
|
x
| | |
|
Body sway
|
x
| |
x
|
x
| | |
|
Enhanced gait and body sway analyses
|
x
| |
x
|
x
| |
At selected sites only
|
|
vHIT
|
x
| |
x
|
x
| |
At selected sites only
|
|
Steps, falls, and fractures
| | |
x
|
x
| |
Total steps, since enrollment or last visit
|
|
BPPV questions
| | |
x
|
x
| | |
|
BPPV testing
| | | |
x
| | |
|
Compliance
| |
x
|
x
| | |
Questionnaire data, number of weekly sessions
|
|
Trial termination form (local)
| | | |
x
| |
Last site visit, at 3 months
|
|
Trial termination form (central)
| | | | |
x
| |
|
Estimated time requirement
|
150 min
|
15 min
|
120 min
|
120 min
|
15 min
|
Total 7 h per participant
|
